Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
Latest news
Date Title
<1m ago NCR : Marcato Capital takes 6.5 percent stake in NCR
<1m ago Football reigned in prime time last week while CBS retained its Nielsen ratings crown
1m ago KORN/FERRY : Korn Ferry Establishes ‘P3’ Specialty Focused Exclusively on Public-Private Partnerships
2m ago SUCCESS : Announces 2015 Plans to Invest In and Produce 30 Internet Short Films & 2 Movies
3m ago ACUMATICA : Raises Over $13 Million in New Funding Round, Led By Bain Capital-Owned MYOB
4m ago HEALTH IT LEADERSHIP SUMMIT : Spotlights Startups With New Pavilion
5m ago HILLTOP : PrimeLending : Inducted into Mortgage Bankers Association's Hall of Honor Program
5m ago DOMINOVAS ENERGY : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
5m ago ANIMALZ : Retractable, Volume-Limiting Headphones Now Available for Kids
6m ago EMBRAER : Brazil's Embraer unveils prototype of new military transport
Latest news
Advertisement
Hot News 
DOMINION MIDSTREAM PARTNERS : Closes Initial Public Offering
TUESDAY SECTOR LAGGARDS : Metals & Mining, Education & Training Services
STRATMIN GLOBAL RESOURCES : Seals Offtake Agreement With Independent Global Graphite Merchant
LIVEDEAL : CEO to Purchase Up to 250,000 Shares of Company's Common Stock in Open-Market Transactions
OCWEN FINANCIAL : Addresses Letter From New York Department of Financial Services
Most Read News
1h ago Wall St. extends bounce-back; S&P above key levels
6h ago Total CEO de Margerie killed in Moscow as jet hits snow plough
16m ago Global shares rally on U.S. tech earnings, ECB purchase plans
1d ago GULFMARK OFFSHORE : Announces Third Quarter 2014 Operating Results
1d ago Chipotle stock dips as sales growth forecasts come down
Most recommended articles
16m ago Global shares rally on U.S. tech earnings, ECB purchase plans
20m agoDJTreasurys, German Bunds Pull Back on Hopes of More ECB Stimulus
20m ago Exclusive- Mexico seeks 1 million sugar export floor in trade dispute with U.S
24m agoDJOil Prices Edge Higher on Chinese Data
27m ago LOCKHEED MARTIN : sees foreign sales reaching 20 percent goal by year-end
Dynamic quotes  
ON
| OFF